- Home
- STM vs ONC Comparison
STM vs ONC Comparison
Compare STM & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STM | ONC |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | Netherlands | Switzerland |
| Employees | 49602 | 12000 |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.9B | 33.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | STM | ONC |
|---|---|---|
| Price | $30.44 | $276.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 11 |
| Target Price | $34.25 | ★ $377.91 |
| AVG Volume (30 Days) | ★ 6.5M | 242.5K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $15.86 | $759.19 |
| Revenue Next Year | $11.23 | $14.51 |
| P/E Ratio | ★ $187.61 | $614.06 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.25 | $196.53 |
| 52 Week High | $35.07 | $385.22 |
Technical Indicators
Market Signals| Indicator | STM | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 41.61 | 28.89 |
| Support Level | $27.45 | $239.25 |
| Resistance Level | $34.23 | $284.51 |
| Average True Range (ATR) | 1.35 | 7.11 |
| MACD | -0.38 | -2.02 |
| Stochastic Oscillator | 8.76 | 1.35 |
Price Performance
Historical ComparisonAbout STM STMicroelectronics N.V.
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconducteurs in France formed STMicroelectronics in 1987. STMicroelectronics is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. It is an especially prominent chip supplier to the industrial and automotive industries.
About ONC BeiGene Ltd. American Depositary Shares
BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.